NCT03792607 (PIRAMIDE) is a clinical trial in Type 2 Diabetes Mellitus, sponsored by Giuditta Benincasa.

Who is sponsoring NCT03792607?

NCT03792607 is sponsored by Giuditta Benincasa.

What condition does NCT03792607 study?

NCT03792607 studies Type 2 Diabetes Mellitus, Cardiovascular Diseases.

Is NCT03792607 still recruiting?

NCT03792607 is currently status unknown. Last updated 18 September 2019.

Last reviewed 2019-09-18 · How we verify

NCT03792607: PIRAMIDE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Network-based Approach in Type 2 Diabetes and Its Cardiovascular Risk

Status unknown Last updated 18 September 2019

What this trial tests

trial in Type 2 Diabetes Mellitus in 35 participants. Status unknown.

Timeline

14 February 2019

Primary endpoint
14 January 2020

14 June 2020

Quick facts

Lead sponsor	Giuditta Benincasa
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	35
Start date	14 February 2019
Primary completion	14 January 2020
Estimated completion	14 June 2020
Sites	1 location across Italy

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Giuditta Benincasa

Who can join

50 and older, any sex, with Type 2 Diabetes Mellitus or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PIRAMIDE study design will test the hypothesis that simultaneous interactions between DNA methylation and microRNAs may hit T2D candidate genes and predict the development of T2D-related cardiovascular complications.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients.
Napoli C, Benincasa G, Schiano C, Salvatore M. · · 2020 · cited 54× · PMID 31665258 · DOI 10.1093/ehjcvp/pvz062
DNA methylation profiling of CD04<sup>+</sup>/CD08<sup>+</sup> T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study.
Benincasa G, Franzese M, Schiano C, Marfella R, et al · · 2020 · cited 16× · PMID 33194177 · DOI 10.1016/j.amsu.2020.10.016
Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery.
Pandey A, Ajgaonkar S, Jadhav N, Saha P, et al · · 2022 · cited 14× · PMID 36297381 · DOI 10.3390/ph15101269
MicroRNA: unveiling novel mechanistic and theranostic pathways in diabetic cardiomyopathy.
De A, Sarkar A, Banerjee T, Bhowmik R, et al · · 2025 · cited 1× · PMID 40771931 · DOI 10.3389/fphar.2025.1613844
Early targeted DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in different stages of impaired glucose homeostasis Cardiovascular Diabetology
Benincasa G, Franzese M, Schiano C, Marfella R, et al · · 2020 · DOI 10.21203/rs.2.24440/v1

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03792607 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Giuditta Benincasa
Last refreshed: 18 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03792607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing